Tacalcitol/ja: Difference between revisions

Tacalcitol/ja
Created page with "タカルシトール"
Tags: Mobile edit Mobile web edit
 
Created page with "{{Antipsoriatics/ja}} {{Vitamin D receptor modulators/ja}}"
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
<languages />
<languages />
<div lang="en" dir="ltr" class="mw-content-ltr">
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
Line 8: Line 6:
| IUPAC_name = (1''S'',3''R'',5''Z'',7''E'',24''R'')-9,10-secocholesta-5,7,10-triene-1,3,24-triol
| IUPAC_name = (1''S'',3''R'',5''Z'',7''E'',24''R'')-9,10-secocholesta-5,7,10-triene-1,3,24-triol
| image = Tacalcitol.svg
| image = Tacalcitol.svg
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
<!--Clinical data-->
<!--Clinical data-->
| tradename =   
| tradename =   
Line 23: Line 19:
| legal_status =   
| legal_status =   
| routes_of_administration = Topical
| routes_of_administration = Topical
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =   
| bioavailability =   
Line 31: Line 25:
| metabolism =   
| metabolism =   
| elimination_half-life =   
| elimination_half-life =   
| excretion =
| excretion =   
</div>  


<div lang="en" dir="ltr" class="mw-content-ltr">
<!--Identifiers-->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|??}}
Line 51: Line 43:
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4446823
| ChemSpiderID      = 4446823
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
<!--Chemical data-->
<!--Chemical data-->
| C=27 | H=44 | O=3  
| C=27 | H=44 | O=3  
Line 63: Line 53:
| StdInChIKey      = BJYLYJCXYAMOFT-RSFVBTMBSA-N
| StdInChIKey      = BJYLYJCXYAMOFT-RSFVBTMBSA-N
}}
}}
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
'''タカルシトール'''('''Tacalcitol''')(1,24-dihydroxyvitamin D<sub>3</sub>)は合成[[vitamin D3|ビタミンD<sub>3</sub>]]類似体である。タカルシトールは'''Curatoderm''''''Bonalfa'''などの名称で販売されている。
'''Tacalcitol''' (1,24-dihydroxyvitamin D<sub>3</sub>) is a synthetic [[vitamin D3|vitamin D<sub>3</sub>]] analog. Tacalcitol is marketed under several names, including '''Curatoderm''' and '''Bonalfa'''.
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
[[WHO Model List of Essential Medicines/ja|世界保健機関の必須医薬品リスト]]に掲載されている。
It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
==メカニズム{{Anchor|Mechanism}}==
==Mechanism==
タカルシトールは、[[keratinocytes/ja|ケラチノサイト]]上の[[vitamin D receptor/ja|ビタミンD受容体]]と相互作用することによって、表皮の過剰な細胞のターンオーバーを抑える。
Tacalcitol reduces excessive cell turnover in the epidermis by interacting with [[vitamin D receptor]]s on [[keratinocytes]].
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
==用途{{Anchor|Uses}}==
==Uses==
皮膚細胞の過剰なターンオーバーを抑える作用があるため、通常、[[psoriasis/ja|乾癬]]や慢性[[chapped lips/ja|ひび割れ唇]]などの重度の乾燥肌の治療薬として、開業医や皮膚科医から処方される。軟膏またはローションとして入手できる。
It is usually prescribed by a general practitioner or dermatologist for the treatment of [[psoriasis]], chronic [[chapped lips]] and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. It is available as an ointment or lotion.
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
また、[[vitiligo/ja|白斑]][[Hailey-Hailey disease/ja|ハイリーハイリー病]]にも使用されている。
It has also been used for [[vitiligo]] and [[Hailey-Hailey disease]].
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
{{Antipsoriatics/ja}}
{{Antipsoriatics}}
{{Vitamin D receptor modulators/ja}}
{{Vitamin D receptor modulators}}
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
{{二次利用|date=11 February 2024}}
[[Category:Secosteroids]]
[[Category:Secosteroids]]
[[Category:Vitamin D]]
[[Category:Vitamin D]]
{{Vitamins}}
{{Vitamins/ja}}
</div>